HR Execs on the Move

University of Illinois Med Center

www.uillinoismedcenter.org

 
University of Illinois Med Center is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Gateway EDI Inc

Gateway EDI Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Shore P.R.N.

North Shore P.R.N. is a Gloucester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Directions Behavioral Health

New Directions Behavioral Health, founded in 1995, is dedicated to helping people find a healthy balance and improve health through positive change. We offer managed behavioral healthcare, employee assistance programs, organizational consulting, and health coaching programs. As behavior change experts, we provide a full range of proven practices to help individuals attain healthier and more balanced lifestyles. In fact, we serve the behavioral health needs of millions of people across the nation. New Directions is one of the fastest growing behavioral health care companies in the nation. Our services have earned national recognition and awards for innovation and best practices. And we are accredited by NCQA as an MBHO and by URAC for health utilization management and case management.

Alturas Analytics

Alturas Analytics is a Moscow, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.